|
POLDIP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.52570195261137E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.03080002498291E-09 |
| Normal-vs-Stage2 |
2.57439999995501E-06 |
| Normal-vs-Stage3 |
8.38209501807796E-11 |
| Normal-vs-Stage4 |
1.82429626960356E-11 |
| Stage1-vs-Stage2 |
6.027000E-01 |
| Stage1-vs-Stage3 |
1.080360E-01 |
| Stage1-vs-Stage4 |
1.506470E-02 |
| Stage2-vs-Stage3 |
5.607200E-01 |
| Stage2-vs-Stage4 |
1.555010E-01 |
| Stage3-vs-Stage4 |
2.367600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.6840978852365E-11 |
| Normal-vs-AfricanAmerican |
6.08779999999864E-05 |
| Normal-vs-Asian |
1.87839999999939E-05 |
| Caucasian-vs-AfricanAmerican |
9.596600E-01 |
| Caucasian-vs-Asian |
4.749600E-01 |
| AfricanAmerican-vs-Asian |
6.270600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.82749959399109E-10 |
| Normal-vs-Female |
4.74750239121136E-11 |
| Male-vs-Female |
4.849000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.4710000035586E-08 |
| Normal-vs-Age(41-60Yrs) |
2.5309000450946E-09 |
| Normal-vs-Age(61-80Yrs) |
7.86615217407416E-12 |
| Normal-vs-Age(81-100Yrs) |
4.408900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.160400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.534000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.675800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.461600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.226000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.840400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.780700E-03 |
| Classical-VS-Follicular |
5.233400E-04 |
| Classical-VS-Other |
6.674600E-01 |
| Classical-VS-Normal |
1.11910000155646E-08 |
| Tall-VS-Follicular |
5.968400E-01 |
| Tall-VS-Other |
8.110400E-01 |
| Tall-VS-Normal |
3.71700004109243E-09 |
| Follicular-VS-Other |
6.037000E-01 |
| Follicular-VS-Normal |
6.46399600512382E-11 |
| Other-VS-Normal |
9.462100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.97320004780011E-09 |
| Normal-vs-N1 |
4.51394477352096E-12 |
| N0-vs-N1 |
1.564380E-02 |
|
|
